G to A hypermutation of hepatitis B virus

Hepatology

Volumn 41, Issue 3, 2005, Pages 626-633

  Noguchi, Chiemi ^a,b   Ishino, Hiromi ^a   Tsuge, Masataka ^a   Fujimoto, Yoshifumi ^c   Imamura, Michio ^a,b   Takahashi, Shoichi ^a,b   Chayama, Kazuaki ^a,b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3G; CYTOSINE DEAMINASE; GAMMA INTERFERON; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG INHIBITION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SUPERNATANT; VIRUS REPLICATION;

ADULT; BASE SEQUENCE; CELL LINE; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEOSIDE DEAMINASES; PROTEINS; REPRESSOR PROTEINS; RNA, MESSENGER; VIRUS REPLICATION;

EID: 14244254668     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20580     Document Type: Article

References (38)

1. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-1344.
2. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39(Suppl 1):S59-S63.
3. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39(Suppl 1):S26-S30.
4. Ganem D, Prince AM. Hepatitis B virus infection: Natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
5. Ganem D, Schneider R. Hepadnaviridae: The Virus and Their Replication. Volume 3. 4th ed. Philadelphia: Lippincott-Raven Publishers, 2001.
6. Skalka AM, Goff SP. Reverse Transcriptase. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1993.
7. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003;424:99-103.
8. Zhang HYB, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003;424:94-98.
9. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003;300:1112.
10. Harris RS, Bishop KN, Shechy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003;113:803-809.
11. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003;114:21-31.
12. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T. APOBEC3G targets specific virus species. J Virol 2004;78:8238-8244.
13. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T. The enzymatic activity of CEM15/Apobec-3G Is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 2003;278:44412-44416.
14. Li J, Potash MJ, Volsky DJ. Functional domains of APOBEC3G required for antiviral activity. J Cell Biochem 2004;92:560-572.
15. Liu B, Yu X, Luo K, Yu Y, Yu XF. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004;78:2072-2081.
16. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004;279:7792-7798.
17. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003;9:1398-1403.
18. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003;12:591-601.
19. Gunther S, Somner G, Plikat U, Imaska A, Wain-Hobson S, Will H, et al. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation. Virology 1997;235:104-108.
20. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004;303:1829.
21. Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamiyasu M, Tazuma S, et al. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. J Med Virol 2004;72:558-565.
22. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis of G to A hypermutation. Biofinformatics 2000;16:400-401.
23. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993;365:566-568.
24. Cabrerizo M, Bartolom J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. HEPATOLOGY 2000;32:116-123.
25. Cabrerizo M, Baetolome J, Carreno V. In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a defetion in the PreS1 region of the viral genome. J Viral Hepatol 2002;9:265-271.
26. Zoulim F, Vitvitski L, Bouffard P, Pichoud C, Rougier P, Lamelin JP, et al. Detection of pre-S1 proteins in peripheral blood mononuclear cells from patients with HBV infection. J Hepatol 1991;12:150-156.
27. Murakami Y, Minami M, Daimon Y, Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004;72:203-214.
28. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. HEPATOLOGY 2003;38:1075-1086.
29. Turelli P, Jost S, Mangeat B, Trono D. Response to comment of "Inhibition of hepatitis B virus replication by APOBEC3G". Science 2004;305:1403b.
30. Rosler C, Kock J, Malim MH, Blum HE, Weizsacker F. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science 2004;305:1403a.
31. Koulinska I, Chaplin B, Mwakagile D, Essex M, Renjifo B. Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retrov 2003;19:1115-1123.
32. Vartanian J, Meterhans A, Sala M, Wain-Hobson S. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 1991;65:1779-1788.
33. Janini M, Rogers M, Birx DR, McCutchan FE. Human Immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells. J Virol 2001;75:7973-7986.
34. Borman A, Quillent C, Charneau P, Kean KM, Clavel F. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G→A. hypermutation during negative-Strand viral DNA synthesis. Virology 1995;208:601-609.
35. Overbaugh J, Jackson S, Papenhausen M, Rudensey LM. Lentiviral genomes with G-to-A hypermutation may result from Taq polymerase errors during polymerase Chain reaction. AIDS Res Hum Retroviruses 1996;17:1605-1613.
36. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999;286:1897-1905.
37. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994;91:3764-3768.
38. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cyrotoxic T lymphocytes. Immunity 1996;4:25-36.